# Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer

> **NCT02551432** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 26 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** pembrolizumab, paclitaxel

## Key facts

- **NCT ID:** NCT02551432
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-12
- **Final completion:** 2018-02
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02551432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02551432, "Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02551432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*